RAPID SCREENING OF CANCER RELATED GENES

与癌细胞相关的基因变化的发现 增加了对检测这些病毒的方法的改进的需求 突变。能够快速、轻松地扫描序列 癌症相关基因有望最终导致更早的检测 以及改进对这种疾病的诊断和治疗。方法将 利用光时质谱学进行开发，以高效和成本 有效地分析一组与癌症相关的基因 时尚。分析的终点是确定准确的 已发生突变的位置和类型。在此项目数据中 将获得至少数百个样本，以创造突变 将基因与病理和基因相关的光谱数据库 诊断/预后，有助于更好地了解癌症的发生。 建议的商业应用： 既有研究，也有医学诊断商业应用 这项研究。对于研究应用，客户将是 制药公司将为提供快速和 选择相关基因突变谱的成本效益知识 患者数据包括对各种治疗剂的反应。 医学诊断测试将基于已知的遗传易感性 对特定疾病的反应以及患者对不同疾病的已知反应 基于基因突变的治疗方法。大型“CLIA”认证临床 实验室将把这种检测作为一种专门的产品提供，基因 提供仪器和专有试剂的TRACE。

Discoveries of he genetic changes associated with cancer cells have increased the need for improvements in the methods to detect these mutations. The ability to quickly and easily scan the sequence of cancer-associated genes promises to lead ultimately to earlier detection as well as improved diagnosis and treatment of the disease. Methods will be develop using time-of-light mass spectrometry to efficiently and cost effectively analyze a set of cancer-related genes in an automated fashion. The endpoint of analysis is the identification of the exact location and type of mutation that has occurred. In this project data will be acquired for at least hundreds of samples to create of mutational spectra database correlating genotype with pathology and diagnosis/prognosis, leading to a better understanding of carcinogenesis. PROPOSED COMMERCIAL APPLICATION: There are both research and medical diagnostic commercial application of this research. For research applications, the clients will be pharmaceutical companies who will pay for a service providing rapid and cost-effective knowledge of mutational spectra of select genes correlated with patient data including response to various therapeutic agents. Medical diagnostic test will be based on known genetic predispositions to specific diseases and on known responses of patients to different therapies based on genetic mutation. Large "CLIA" certified clinical laboratories would offer the test as a specialized product, with Gene Trace providing instrumentation and proprietary reagents.